EGFR and non-small cell lung carcinoma: We look forward to the results of the two ongoing randomized controlled trials focused on adjuvant TKI versus chemotherapy in patients with stageII~IIIA EGFR-mutated NSCLC, the Chinese CTONG1104 study and the Japanese IMPACT study.